Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms

Kidney International

Volumn 64, Issue 6, 2003, Pages 2238-2243

  Bammens, Bert ^a   Evenepoel, Pieter ^a   Verbeke, Kristin ^a   Vanrenterghem, Yves ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Peritoneal dialysis; Protein bound solutes; Residual renal function; Symptoms

Indexed keywords

BETA 2 MICROGLOBULIN; CREATININE; NITROGEN; PARA CRESOL; PHOSPHATE; UREA;

ADULT; ARTICLE; BLOOD ANALYSIS; CALCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; HUMAN; KIDNEY CLEARANCE; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; QUESTIONNAIRE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; UREMIA;

EID: 0344945410     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00310.x     Document Type: Article

References (46)

1. NATIONAL KIDNEY FOUNDATION: NKF-DOQI Clinical Practice Guidelines for Peritoneal Dialysis Adequacy. Am J Kidney Dis 30(Suppl 2):S67-S136, 1997
2. NATIONAL KIDNEY FOUNDATION: NKF-K/DOQI Clinical Practice Guidelines for Peritoneal Dialysis Adequacy: Update 2000. Am J Kidney Dis 37(Suppl 1):S65-S136, 2001
3. CANUSA PD STUDY GROUP: Adequacy of dialysis and nutrition in continuous peritoneal dialysis: Association with clinical outcomes. J Am Soc Nephrol 7:198-207, 1996
4. BARGMAN JM, THORPE KE, CHURCHILL DN, FOR THE CANUSA PD STUDY GROUP: Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: A reanalysis of the CANUSA study. J Am Soc Nephrol 12:2158-2162, 2001
5. PANIAGUA R, AMATO D, VONESH E, et al: Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 13:1307-1320, 2002
6. ATES K, NERGIZOGLU G, KEVEN K, et al: Effect of fluid and sodium removal on mortality in peritoneal dialysis patients. Kidney Int 60:767-776, 2001
7. CHUNG SH, HEIMBÜRGER O, STENVINKEL P, et al: Association between residual renal function, inflammation and patient survival in new peritoneal dialysis patients. Nephrol Dial Transplant 18:590-597, 2003
8. WANG T, LINDHOLM B: Beyond CANUSA, DOQI, ADEMEX: What's next? Perit Dial Int 22:555-562, 2002
9. HEIMBÜRGER O: The negative results of the ADEMEX study may be positive for peritoneal dialysis. Time for a paradigm shift in the focus of peritoneal dialysis adequacy. Perit Dial Int 22:546-548, 2002
10. PIRAINO B: ADEMEX: How should it change our practice? Pent Dial Int 22:552-554, 2002
11. CHURCHILL DN: The ADEMEX study: Make haste slowly. J Am Soc Nephrol 13:1415-1418, 2002
12. VANHOLDER R, ARGILES A, BAURMEISTER U, et al: Uremic toxicity: Present state of the art. Int J An Organs 24:695-725, 2002
13. 2- microglobulin. Immunochemistry 11:111-117, 1974
14. ENOMOTO A, TAKEDA M, TOJO A, et al: Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. J Am Soc Nephrol 13:1711-1720, 2002
15. VANHOLDER R, DE SMET R, LAMEIRE N: Protein bound uremic solutes: The forgotten toxins. Kidney Int 59(Suppl 78):S266-S270, 2001
16. VANHOLDER R, DE SMET R, WATERLOOS MA, et al: Mechanisms of uremic inhibition of phagocyte reactive species production: Characterization of the role of p-cresol. Kidney Int 47:510-517, 1995
17. DOU L, CERINI C, BRUNET P, et al: P-cresol, a uremic toxin, decreases endothelial cell response to inflammatory cytokines. Kidney Int 62:1999-2009, 2002
18. DE SMET R, VAN KAER J, VAN VLEM B, et al: Toxicity of free p-cresol: A prospective and cross-sectional analysis. Clin Chem 49:470-478, 2003
19. DAVIES SJ, PHILLIPS L, NAISH PF, RUSSELL GI: Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival. Nephrol Dial Transplant 17:1085-1092, 2002
20. DU BOIS D, DU BOIS EF: A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 17:863-971, 1916
21. WATSON PE, WATSON ID, BATT RD: Total body water volumes for adult males and females estimated from simple anthropometric measurements. Am J Clin Nutr 33:27-39, 1980
22. BERGSTRÖM J, HEIMBURGER O, LINDHOLM B: Calculation of the protein equivalent of total nitrogen appearance from urea appearance. Which formulas should be used? Perit Dial Int 18:467-473, 1998
23. TUCCI A, CORINALDESI R, STANGHELLINI V, et al: Helicobacter pylori infection and gastric function in patients with chronic idiopathic dyspepsia. Gastroenterology 103:768-774, 1992
24. STANGHELLINI V, TOSETTI C, PATERNICO A, et al: Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology 110:1036-1042, 1996
25. TACK J, PIESSEVAUX H, COULIE B, et al: Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 115:1346-1352, 1998
26. FLESSNER MF: Peritoneal transport physiology: Insights from basic research. J Am Soc Nephrol 2:122-135, 1991
27. KREDIET RT, KOOMEN GCM, KOOPMAN MG, et al: The peritoneal transport of serum proteins and neutral dextran in CAPD patients. Kidney Int 35:1064-1072, 1989
28. IMHOLZ ALT, KOOMEN GCM, STRUIJK DG, et al: Effect of dialysate osmolarity on the transport of low-molecular weight solutes and proteins during CAPD. Kidney Int 43:1339-1346, 1993
29. MONTINI G, AMICI G, MILAN S, et al: Middle molecule and small protein removal in children on peritoneal dialysis. Kidney Int 61:1153-1159, 2002
30. BOUTS AHM, DAVIN JC, GROOTHOFF JW, et al: Standard peritoneal permeability analysis in children. J Am Soc Nephrol 11:943-950, 2000
31. KIM DJ, HO DO J, HUH W, et al: Dissociation between clearances of small and middle molecules in incremental peritoneal dialysis. Perit Dial Int 21:462-466, 2001
32. DE SMET R, GLORIEUX G, HSU C, VANHOLDER R: P-cresol and uric Acid: Two old uremic toxins revisited. Kidney Int 52(Suppl 62):S8-S11, 1997
33. LESAFFER G, DE SMET R, LAMEIRE N, et al: Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane. Nephrol Dial Transplant 15:50-57, 2000
34. MAEDA K, SHINZATO T, OTA T, et al: Beta-2-microglobulin generation rate and clearance rate in maintenance hemodialysis patients. Nephron 56:118-125, 1990
35. 2- microglobulin kinetics in end-stage renal failure. Kidney Int 39:909-919, 1991
36. XU XQ, GRUNER N, AL-BASHIR A, et al: Determination of extra renal clearance and generation rate of beta2-microglobulin in hemodialysis patients using a kinetic model. Artif Organs 47:623-627, 2001
37. EVENEPOEL P, CLAUS D, GEYPENS B, et al: Amount and fate of egg protein escaping assimilation in the small intestine of humans. Am J Physiol 277:G935-G943, 1999
38. BIRKETT A, MUIR J, PHILLIPS J, et al: Resistant starch lowers fecal concentrations of ammonia and phenols in humans. Am J Clin Nutr 63:766-772, 1996
39. CUMMINGS JH, HILL MJ, BONE ES, et al: The effect of meat protein and dietary fiber on colonic function and metabolism. II. Bacterial metabolites in feces and urine. Am J Clin Nutr 32:2094-2101, 1979
40. ZEHNDER C, GUTZWILLER JP, RENGGLI K: Hemodiafiltration - A new treatment option for hyperphosphatemia in hemodialysis patients. Clin Nephrol 52:152-159, 1999
41. MUCSI I, HERCZ G, ULDALL R, et al: Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 53:1399-1404, 1998
42. GALLAR P, ORTEGA O, GUTIERREZ M, et al: Influencing factors in the control of phosphorus in peritoneal dialysis. Therapeutic options. Nefrologia 20:355-361, 2000
43. GUTZWILLER JP, SCHNEDITZ D, HUBER AR, et al: Estimating phosphate removal in haemodialysis: an additional tool to quantify dialysis dose. Nephrol Dial Transplant 17:1037-1044, 2002
44. HO-DAC-PANNEKEET MM, KOOPMANS JG, STRUIJK DG, KREDIET RT: Restriction coefficients of low molecular weight solutes and macromolecules during peritoneal dialysis. Adv Perit Dial 13:72-76, 1997
45. DE SMET R, DAVID F, SANDRA P, et al: A sensitive HPLC method for the quantification of free and total p-cresol in patients with chronic renal failure. Clin Chim Acta 278:1-21, 1998
46. HIDA M, AIBA Y, SAWAMURA S, et al: Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin®, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 74:349-355, 1996